Oncolytics' pancreatic cancer trial hits endpoint; Pfizer completes Excaliard acquisition;

 @FierceBiotech: Idera wins FDA green light for Phase II psoriasis drug test. News | Follow@FierceBiotech

 @RyanMFierce: Here's Novartis' PR on data it will present at SABCS and ASH. Release | Follow@RyanMFierce

 @MaureenFierce: Of the 88 medicines and vaccines in development for HIV/AIDS, 49 are antivirals and 27 are vaccines. Release | Follow@MaureenFierce

 @MarkHFierce: Interesting. First South Africa, and now Obama sets a new goal for fighting AIDS globally. Here's the Reuters story. Article| Follow @MarkHFierce

> Oncolytics Biotech says a Phase II study of Reolysin in combination with gemcitabine (Gemzar) for patients with advanced pancreatic cancer successfully reached its primary endpoint. Release

> Pfizer ($PFE) has completed its acquisition of Excaliard Pharmaceuticals. Pfizer release

> AstraZeneca has tapped outsourcing firm Cognizant to take on a range of duties for the London-based drug giant, which aims to "streamline" its clinical development work, a company official stated. Article

Pharma News

 @FiercePharma: Short-term praise and long-term questions for Shire from the FTNews | Follow @FiercePharma

> Report shows Big Pharma's patent cliff in graphic detail. News

> Sanofi spikes authorized Lovenox generic. Article

> Drug retailers sue Pfizer, Teva over Effexor XR copycats. Story

> Shire shrugs off blame for Adderall shortage. News

> Report shows Big Pharma's patent cliff in graphic detail. Report

> Ranbaxy's silence on Teva profit-sharing draws questions. Report

And Finally... Cell surface molecules known as ephrins may be the key to guiding injected adult stem cells treatments to envelop an injured muscle, scientists now theorize, which could maximize their use as a tool for repair. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.